Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan

Core Viewpoint - Poxel SA has confirmed the drawdown of €3.75 million under the Additional Tranche D PDR bond issue as part of its continuation plan approved by the Lyon Commercial Court on January 22, 2026 [1] Financing Details - Poxel has previously issued €0.5 million of Tranche D PDR bonds on February 16, 2026, and plans to issue an additional €0.5 million on March 26, 2026 [2] - The Tranche D PDR is a result of a contractual amendment to the IPF bond financing initiated in September 2024, aimed at securing the company's operations [3] - The financing aims to cover the company's operational costs and liabilities during the continuation plan, alongside other financing operations and cost reductions [5] Key Terms of Tranche D PDR - The cash interest rate for Tranche D PDR is set at 0%, with a capitalized interest rate of 35% and a commitment fee of 10% [7] - An exit fee of 13.7% is applicable, calculated based on the total amount of bonds issued [7] - The allocation rate of Twymeeg royalties for the repayment of the IPF bond financing is set at 90% [7] - The issuance of share subscription warrants is planned for Poxel's next general meeting [4] Company Overview - Poxel SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for chronic diseases with metabolic pathophysiology, including MASH and rare metabolic disorders [5] - The company’s product PXL065 has met its primary endpoint in a Phase 2 trial for MASH, while PXL770 is being developed for rare diseases [5] - Poxel's first-in-class product, TWYMEEG® (Imeglimin), is marketed in Japan for type 2 diabetes, with expected royalties and sales-based payments [5]